Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 247

1.

In Vitro Activity and MIC of Sitafloxacin against Multidrug-Resistant and Extensively Drug-Resistant Mycobacterium tuberculosis Isolated in Thailand.

Leechawengwongs M, Prammananan T, Jaitrong S, Billamas P, Makhao N, Thamnongdee N, Thanormchat A, Phurattanakornkul A, Rattanarangsee S, Ratanajaraya C, Disratthakit A, Chaiprasert A.

Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e00825-17. doi: 10.1128/AAC.00825-17. Print 2018 Jan.

2.

Role of gyrB Mutations in Pre-extensively and Extensively Drug-Resistant Tuberculosis in Thai Clinical Isolates.

Disratthakit A, Prammananan T, Tribuddharat C, Thaipisuttikul I, Doi N, Leechawengwongs M, Chaiprasert A.

Antimicrob Agents Chemother. 2016 Aug 22;60(9):5189-97. doi: 10.1128/AAC.00539-16. Print 2016 Sep.

3.

Molecular characterization of mutations associated with resistance to second-line tuberculosis drug among multidrug-resistant tuberculosis patients from high prevalence tuberculosis city in Morocco.

Oudghiri A, Karimi H, Chetioui F, Zakham F, Bourkadi JE, Elmessaoudi MD, Laglaoui A, Chaoui I, El Mzibri M.

BMC Infect Dis. 2018 Feb 27;18(1):98. doi: 10.1186/s12879-018-3009-9.

4.

Susceptibility testing breakpoints for Mycobacterium tuberculosis categorize isolates with resistance mutations in gyrA as susceptible to fluoroquinolones: implications for MDR-TB treatment and the definition of XDR-TB.

Niward K, Ängeby K, Chryssanthou E, Paues J, Bruchfeld J, Jureen P, Giske CG, Kahlmeter G, Schön T.

J Antimicrob Chemother. 2016 Feb;71(2):333-8. doi: 10.1093/jac/dkv353. Epub 2015 Nov 3.

PMID:
26538509
5.

Early detection of multidrug- and pre-extensively drug-resistant tuberculosis from smear-positive sputum by direct sequencing.

Chen J, Peng P, Du Y, Ren Y, Chen L, Rao Y, Wang W.

BMC Infect Dis. 2017 Apr 24;17(1):300. doi: 10.1186/s12879-017-2409-6.

6.

In Vitro Drug Susceptibility of Bedaquiline, Delamanid, Linezolid, Clofazimine, Moxifloxacin, and Gatifloxacin against Extensively Drug-Resistant Tuberculosis in Beijing, China.

Pang Y, Zong Z, Huo F, Jing W, Ma Y, Dong L, Li Y, Zhao L, Fu Y, Huang H.

Antimicrob Agents Chemother. 2017 Sep 22;61(10). pii: e00900-17. doi: 10.1128/AAC.00900-17. Print 2017 Oct.

7.

Molecular characterization of fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolates from Shanghai, China.

Zhu C, Zhang Y, Shen Y, Siu GK, Wu W, Qian X, Deng G, Xu Y, Lau R, Fan X, Zhang W, Lu H, Yam WC.

Diagn Microbiol Infect Dis. 2012 Jul;73(3):260-3. doi: 10.1016/j.diagmicrobio.2012.03.025. Epub 2012 May 4.

PMID:
22560167
8.

Prevalence of gyrA and B gene mutations in fluoroquinolone-resistant and -sensitive clinical isolates of Mycobacterium tuberculosis and their relationship with MIC of ofloxacin.

Singh P, Jain A, Dixit P, Prakash S, Jaiswal I, Venkatesh V, Singh M.

J Antibiot (Tokyo). 2015 Jan;68(1):63-6. doi: 10.1038/ja.2014.95. Epub 2014 Jul 23.

PMID:
25052485
9.

Characterization of gyrA and gyrB mutations associated with fluoroquinolone resistance in Mycobacterium tuberculosis isolates from Morocco.

Chaoui I, Oudghiri A, El Mzibri M.

J Glob Antimicrob Resist. 2018 Mar;12:171-174. doi: 10.1016/j.jgar.2017.10.003. Epub 2017 Oct 13.

PMID:
29033301
10.

Comparison of In Vitro Activity and MIC Distributions between the Novel Oxazolidinone Delpazolid and Linezolid against Multidrug-Resistant and Extensively Drug-Resistant Mycobacterium tuberculosis in China.

Zong Z, Jing W, Shi J, Wen S, Zhang T, Huo F, Shang Y, Liang Q, Huang H, Pang Y.

Antimicrob Agents Chemother. 2018 Jul 27;62(8). pii: e00165-18. doi: 10.1128/AAC.00165-18. Print 2018 Aug.

11.

Second-line anti-tuberculosis drug resistance and its genetic determinants in multidrug-resistant Mycobacterium tuberculosis clinical isolates.

Bakuła Z, Napiórkowska A, Kamiński M, Augustynowicz-Kopeć E, Zwolska Z, Bielecki J, Jagielski T.

J Microbiol Immunol Infect. 2016 Jun;49(3):439-44. doi: 10.1016/j.jmii.2015.04.003. Epub 2015 May 15.

12.

Sequence Analysis of Fluoroquinolone Resistance-Associated Genes gyrA and gyrB in Clinical Mycobacterium tuberculosis Isolates from Patients Suspected of Having Multidrug-Resistant Tuberculosis in New Delhi, India.

Singhal R, Reynolds PR, Marola JL, Epperson LE, Arora J, Sarin R, Myneedu VP, Strong M, Salfinger M.

J Clin Microbiol. 2016 Sep;54(9):2298-305. doi: 10.1128/JCM.00670-16. Epub 2016 Jun 22.

13.

Second-line drug susceptibilities of multidrug-resistant tuberculosis strains isolated in Thailand: an update.

Chaiprasert A, Srimuang S, Tingtoy N, Makhao N, Sirirudeeporn P, Tomnongdee N, Theankeaw O, Charoensook S, Leechawengwongs M, Prammananan T.

Int J Tuberc Lung Dis. 2014 Aug;18(8):961-3. doi: 10.5588/ijtld.13.0197.

PMID:
25199012
14.

Frequency and patterns of second-line resistance conferring mutations among MDR-TB isolates resistant to a second-line drug from eSwatini, Somalia and Uganda (2014-2016).

Kateete DP, Kamulegeya R, Kigozi E, Katabazi FA, Lukoye D, Sebit SI, Abdi H, Arube P, Kasule GW, Musisi K, Dlamini MG, Khumalo D, Joloba ML.

BMC Pulm Med. 2019 Jul 10;19(1):124. doi: 10.1186/s12890-019-0891-x.

15.

Susceptibility testing of extensively drug-resistant and pre-extensively drug-resistant Mycobacterium tuberculosis against levofloxacin, linezolid, and amoxicillin-clavulanate.

Ahmed I, Jabeen K, Inayat R, Hasan R.

Antimicrob Agents Chemother. 2013 Jun;57(6):2522-5. doi: 10.1128/AAC.02020-12. Epub 2013 Mar 18.

16.

Extensively drug-resistant tuberculosis in Myanmar: burden and mutations causing second-line drug resistance.

Ei PW, Aung WW, Nyunt WW, Swe TL, Htwe MM, Win SM, Aung ST, Chang CL, Lee HY, Lee JS.

Int J Tuberc Lung Dis. 2018 Jan 1;22(1):47-53. doi: 10.5588/ijtld.17.0321.

PMID:
29297425
17.

Trends in fluoroquinolone resistance of Mycobacterium tuberculosis complex in a Taiwanese medical centre: 1995-2003.

Huang TS, Kunin CM, Shin-Jung Lee S, Chen YS, Tu HZ, Liu YC.

J Antimicrob Chemother. 2005 Dec;56(6):1058-62. Epub 2005 Oct 4.

PMID:
16204341
18.

Molecular detection of fluoroquinolone-resistance in multi-drug resistant tuberculosis in Cambodia suggests low association with XDR phenotypes.

Surcouf C, Heng S, Pierre-Audigier C, Cadet-Daniel V, Namouchi A, Murray A, Gicquel B, Guillard B.

BMC Infect Dis. 2011 Sep 28;11:255. doi: 10.1186/1471-2334-11-255.

19.

Should moxifloxacin be used for the treatment of extensively drug-resistant tuberculosis? An answer from a murine model.

Poissy J, Aubry A, Fernandez C, Lott MC, Chauffour A, Jarlier V, Farinotti R, Veziris N.

Antimicrob Agents Chemother. 2010 Nov;54(11):4765-71. doi: 10.1128/AAC.00968-10. Epub 2010 Aug 30.

20.

Detection by GenoType MTBDRsl test of complex mechanisms of resistance to second-line drugs and ethambutol in multidrug-resistant Mycobacterium tuberculosis complex isolates.

Brossier F, Veziris N, Aubry A, Jarlier V, Sougakoff W.

J Clin Microbiol. 2010 May;48(5):1683-9. doi: 10.1128/JCM.01947-09. Epub 2010 Mar 24.

Supplemental Content

Support Center